Association between circulating tumor cells in the peripheral blood and the prognosis of gastric cancer patients: a meta-analysis

Abstract

Background: Research on the correlation between circulating tumor cells (CTCs) and gastric cancer (GC) has increased rapidly in recent years. However, whether CTCs are associated with GC patient prognosis is highly controversial. Objective: This study aims to evaluate the value of CTCs to predict the prognosis of GC patients. Design: A meta-analysis. Data Sources and Methods: We searched the PubMed, Embase, and Cochrane Library databases for studies that reported the prognostic value of CTCs in GC patients before October 2022. The association between CTCs and overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS) and progression-free survival (PFS) of GC patients was assessed. Subgroup analyses were stratified by sampling times (pre-treatment and post-treatment), detection targets, detection method, treatment method, tumor stage, region, and HR (Hazard Ratio) extraction methods. Sensitivity analysis was performed by removing individual studies to assess the stability of the results. Publication bias was evaluated using funnel plots, Egger’s test, and Begg’s test. Results: We initially screened 2000 studies, of which 28 were available for further analysis, involving 2383 GC patients. The pooled analysis concluded that the detection of CTCs was associated with poor OS (HR = 1.933, 95% CI 1.657–2.256, p < 0.001), DFS/RFS (HR = 3.228, 95% CI 2.475–4.211, p < 0.001), and PFS (HR = 3.272, 95% CI 1.970–5.435, p < 0.001). Furthermore, the subgroup analysis stratified by tumor stage ( p < 0.01), HR extraction methods ( p < 0.001), detection targets ( p < 0.001), detection method ( p < 0.001), sampling times ( p < 0.001), and treatment method ( p < 0.001) all showed that CTC detection was associated with poor OS and DFS/RFS for GC patients. Furthermore, the study showed that CTCs were associated with the poor DFS/RFS of GC when CTCs were detected for patients from Asian or No-Asian regions ( p < 0.05). In addition, higher CTCs predicted poorer OS for GC patients who are from Asian regions ( p < 0.001), but without statistical difference for GC patients from No-Asian regions ( p = 0.490). Conclusion: CTC detection in peripheral blood was associated with poor OS, DFS/RFS, and PFS in patients with GC.

Dual targeting negative enrichment strategy for highly sensitive and purity detection of CTCs

“…CTCs, originating from malignant tissue, traverse into the peripheral blood circulation and disseminate to distant tissues ( McGranahan and Swanton, 2017 ). CTC, thus, emerges as a valuable liquid biopsy biomarker with multifaceted applications in early cancer detection ( Lawrence et al, 2023 ), diagnosis ( Gazzaniga et al, 2014 ; Xu et al, 2020 ; Deng et al, 2022 ), prognosis ( Jin et al, 2019 ; Pantel et al, 2019 ; Jin et al, 2023 ), monitoring ( Punnoose et al, 2012 ; Castro-Giner and Aceto, 2020 ), and treatment ( Yu et al, 2014 ; Praharaj et al, 2018 ; Alix-Panabières and Pantel, 2021 ).…”